Novocure's non-invasive cancer device Ok'd in Europe for mesothelioma

Nov. 11, 2020 8:51 AM ETNovoCure Limited (NVCR)By: Vandana Singh, SA News Editor8 Comments
  • Novocure (NASDAQ:NVCR) has received the CE Mark for the NovoTTF-100L system, for the commercialization of the device as a first-line treatment in combination with Eli Lilly's Alimta (pemetrexed) and platinum-based chemotherapy for malignant pleural mesothelioma (MPM), in the European Union and Switzerland.
  • The FDA approved the NovoTTF-100L System (known as Optune Lua) for MPM in May 2019 under the Humanitarian Device Exemption pathway.
  • NovoTTF-100L is a noninvasive, antimitotic cancer treatment for MPM, and delivers Tumor Treating Fields using electric fields to disrupt cell division. These Fields does not stimulate or heat tissue and targets dividing cancer cells of a specific size, thus causes minimal damage to healthy cells.
  • Shares are up 4% in premarket.

Recommended For You

Comments (8)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.